The current situation:: Erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer

被引:59
作者
Comis, RL [1 ]
机构
[1] Drexel Univ, Coll Med, Clin Trials Res Ctr, Chester, PA 19013 USA
关键词
non-small cell lung cancer; erlotinib; gefitinib; epidermal growth factor receptor;
D O I
10.1634/theoncologist.10-7-467
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:467 / 470
页数:4
相关论文
共 22 条
[1]  
*ASTRAZENECA PHARM, 2005, MARK AUTH APPL WITHD
[2]   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[3]  
Clark GM, 2005, J CLIN ONCOL, V23, p628S
[4]   FDA drug approval summary:: Erlotinib (Tarceva®) tablets [J].
Cohen, MH ;
Johnson, JR ;
Chen, YF ;
Sridhara, R ;
Pazdur, R .
ONCOLOGIST, 2005, 10 (07) :461-466
[5]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[6]   A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer [J].
Fujino, S ;
Enokibori, T ;
Tezuka, N ;
Asada, Y ;
Inoue, S ;
Kato, H ;
Mori, A .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (12) :2070-2074
[7]  
*GEN INC, 2005, TARC ERL TABL PACK I
[8]  
Hamilton M, 2005, P AM ASSOC CANC RES, V46, P56
[9]  
HECHT JR, 2004, J CLIN ONCOL, V22, P248
[10]   Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications [J].
Kosaka, T ;
Yatabe, Y ;
Endoh, H ;
Kuwano, H ;
Takahashi, T ;
Mitsudomi, T .
CANCER RESEARCH, 2004, 64 (24) :8919-8923